tbuckley/cabot-search huggingface dataset:
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features
Authors: Eduardo Vilar‐Gomez, Carlos J. Pirola, Silvia Sookoian, Laura A. Wilson, Tiebing Liang, Naga Chalasani
Journal: Hepatology (2022)

It is unclear whether rs738409 (p.I148M) missense variant in patatin-like phospholipase domain-containing 3 rs738409 promotes fibrosis development by triggering specific fibrogenic pathways or by creating an unfavorable microenvironment by promoting steatosis, inflammation, and ultimately fibrosis. We tested the hypothesis that intermediate histologic traits, including steatosis, lobular and portal inflammation, and ballooning may determine the effect of rs738409 on liver fibrosis among individuals with biopsy-proven NAFLD. Causal mediation models including multiple mediators in parallel or sequentially were performed to examine the effect of rs738409, by decomposing its total effect on fibrosis severity into direct and indirect effects, mediated by histology traits in 1153 non-Hispanic White patients. Total effect of rs738409 on fibrosis was β = 0.19 (95% CI: 0.09-0.29). The direct effect of rs738409 on fibrosis after removing mediators' effects was β = 0.09 (95% CI: 0.01-0.17) and the indirect effect of rs738409 on fibrosis through all mediators' effects were β = 0.010 (95% CI: 0.04-0.15). Among all mediators, the greatest estimated effect size was displayed by portal inflammation (β = 0.09, 95% CI: 0.05-0.12). Among different sequential combinations of histology traits, the path including lobular inflammation followed by ballooning degeneration displayed the most significant indirect effect (β = 0.023, 95% CI: 0.011-0.037). Mediation analysis in a separate group of 404 individuals with biopsy-proven NAFLD from other races and ethnicity showed similar results. In NAFLD, nearly half of the total effect of the rs738409 G allele on fibrosis severity could be explained by a direct pathway, suggesting that rs738409 may promote fibrosis development by activating specific fibrogenic pathways. A large proportion of the indirect effect of rs738409 on fibrosis severity is mediated through portal inflammation.
Bevacizumab in High-Risk Corneal Transplantation
Authors: Thomas H. Dohlman, Matthew McSoley, Francisco Amparo, Tatiana Carreno-Galeano, Mengyu Wang, Mohammad Dastjerdi, Rohan Bir Singh, Giulia Coco, Antonio Di Zazzo, Hasanain Shikari, Ujwala Saboo, Kimberly Sippel, Jessica Ciralsky, Sonia H. Yoo, Matheus Sticca, Tais H. Wakamatsu, Somasheila Murthy, Pedram Hamrah, Ula Jurkunas, Joseph B. Ciolino, Jose A.P. Gomes, Victor L. Perez, Jia Yin, Reza Dana
Journal: Ophthalmology (2022)
SIMPLE AND COMPLEX MITRAL VALVE PROLAPSE: ASSESSMENT BY THREE-DIMENSIONAL TRANSESOPHAGEAL ECHOCARDIOGRAPHY
Authors: Antonio Vitarelli, Lidia Capotosto, Bich Lien Nguyen, Gaetano Tanzilli, Nicola Viceconte, Massimo Mancone, Enrico Mangieri, Maria Ciardi, Claudio Mastroianni, Fabio Miraldi
Journal: Journal of the American College of Cardiology (2022)
Inflammation, Serum Iron, and Risk of Mortality and Cardiovascular Events in Nondialysis CKD Patients
Authors: Guy Rostoker, Fanny Lepeytre, Jacques Rottembourg
Journal: Journal of the American Society of Nephrology (2022)

In their recently published article in JASN, Guedes et al.1 analyzed data from the Chronic Kidney Disease Outcomes and Practice Patterns Study (comprising 5145 patients from France, Germany, United States, and Brazil, enrolled between 2013 and 2017). They found that, in patients with nondialysis CKD, there was an association between transferrin saturation ≤15% and increased all-cause mortality and major cardiovascular adverse events, regardless of anemia. In addition, transferrin saturation ≥46% and ferritin ≥300 ng/ml tended to be associated with increased all-cause mortality, but these associations were NS. These results are in line with biologic data showing the pivotal role of iron in DNA synthesis and repair2 as an increase in ferroptosis in an iron-overloaded state.3 In addition to being biomarkers widely used by nephrologists to monitor iron storage (ferritin) and iron availability (transferrin and transferrin saturation) in patients with nondialysis and dialysis CKD, ferritin, transferrin, and transferrin saturation are also acute-phase reactants.4 Inflammation is common in patients with nondialysis CKD and is implicated in the pathophysiology of cardiovascular events in both patients with and without renal disease.4 These authors performed survival analyses using Cox proportional hazard models adjusted for various confounders known to influence survival in patients with nondialysis CKD.1 We suggest inclusion of inflammation as a covariate, in addition to the factors in their models, because it is an important confounding factor in the measurement of ferritin and transferrin saturation that is also known to influence mortality and cardiovascular events in patients with nondialysis CKD. Detailed analyses using various biomarkers of inflammation could be informative to fully explore the association between current serum iron biomarkers and mortality, cardiovascular events, or both in patients with nondialysis CKD. Disclosures G. Rostoker reports receiving research funding, via scientific presentations, from Amgen, Astellas, Baxter, Hemotech, Hospal-Gambro, Nipro, Physidia France, and Theradial; having consultancy agreements with Astellas France (via the board on roxadustat 2019–2021); serving on speakers bureaus for Astellas and Baxter; and receiving honoraria from Amgen, Astellas, Roche, and Sanofi. All remaining authors have nothing to disclose. Funding None.
IIT is ideally positioned to explain perceptual phenomena
Authors: Andrew M Haun
Journal: Behavioral and Brain Sciences (2022)

Abstract The target article's critique of the integrated information theory (IIT) of consciousness is misguided on several fronts, which I hope are addressed in other comments, but here I focus on the connection (or supposed lack thereof) between IIT and rigorous phenomenology, and IIT's connection to the psychophysics of perception.
AGE AS A PREDICTOR OF MORTALITY IN PATIENTS ADMITTED WITH COVID-19, A RETROSPECTIVE STUDY OF 6,000 PATIENTS
Authors: Mujahed Abualfoul, Yi Zhao, Victor Canela, Lawrence M. Hoang, Sri Naga Pavani Prathivada, Michael Vu, Lucas Wang, Priyanka Acharya, Manavjot Singh Sidhu
Journal: Journal of the American College of Cardiology (2022)
A neurodegenerative disease landscape of rare mutations in Colombia due to founder effects
Authors: Juliana Acosta-Uribe, David Aguillón, J. Nicholas Cochran, Margarita Giraldo, Lucía Madrigal, Bradley W. Killingsworth, Rijul Singhal, Sarah Labib, Diana Alzate, Lina Velilla, Sonia Moreno, Gloria P. García, Amanda Saldarriaga, Francisco Piedrahita, Liliana Hincapié, Hugo E. López, Nithesh Perumal, Leonilde Morelo, Dionis Vallejo, Juan Marcos Solano, Eric M. Reiman, Ezequiel I. Surace, Tatiana Itzcovich, Ricardo Allegri, Raquel Sánchez-Valle, Andrés Villegas-Lanau, Charles L. White, Diana Matallana, Richard M. Myers, Sharon R. Browning, Francisco Lopera, Kenneth S. Kosik
Journal: Genome Medicine (2022)

The Colombian population, as well as those in other Latin American regions, arose from a recent tri-continental admixture among Native Americans, Spanish invaders, and enslaved Africans, all of whom passed through a population bottleneck due to widespread infectious diseases that left small isolated local settlements. As a result, the current population reflects multiple founder effects derived from diverse ancestries.
CLO22-084: Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer: A Multicenter Retrospective Analysis With Focus on Elderly Patients Subgroup
Authors: Carlo Signorelli, Federica Zoratto, Donatello Gemma, Rosa Saltarelli, Maria Grazia Morandi, Roberta Grande, Gian Paolo Spinelli, Salvatore De Marco, Isabella Sperduti, Mario Giovanni Chilelli, Anna Ceribelli, Enzo Maria Ruggeri
Journal: Journal of the National Comprehensive Cancer Network (2022)

"CLO22-084: Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer: A Multicenter Retrospective Analysis With Focus on Elderly Patients Subgroup" published on 31 Mar 2022 by National Comprehensive Cancer Network.
SEVERE CORONARY CALCIFICATION IS ASSOCIATED WITH HIGHER INCIDENCE OF DEVICE-ORIENTED ADVERSE CLINICAL EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTION
Authors: Takako Nagata, Yoshiyasu Minami, Kiyoshi Asakura, Masahiro Katamine, Daisuke Kinoshita, Junya Ako
Journal: Journal of the American College of Cardiology (2022)
18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography in Acute Aortic Syndrome
Authors: Maaz B J Syed, Alexander J Fletcher, Samuel Debono, Rachel O Forsythe, Michelle C Williams, Marc R Dweck, Anoop S V Shah, Mark G Macaskill, Adriana Tavares, Martin A Denvir, Kelvin Lim, William A Wallace, Jakub Kaczynski, Tim Clark, Stephanie L Sellers, Neil Masson, Orwa Falah, Roderick T A Chalmers, Andrew L Tambyraja, Edwin J R van Beek, David E Newby
Journal: JACC. Cardiovascular imaging (2022)
THE 2017 ACC/AHA HYPERTENSION GUIDELINES AND CHA2DS2-VASC UP-SCORING IN PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE NCDR® PINNACLE® REGISTRY
Authors: Krishna Pundi, Kensey Gosch, Natasha Din, Alexander Perino, Phillip G. Jones, Nihar R. Desai, Thomas M. Maddox, Mintu Turakhia
Journal: Journal of the American College of Cardiology (2022)
The Russian invasion of Ukraine and its public health consequences
Authors: David A. Leon, Dmitri Jdanov, Christopher J. Gerry, Pavel Grigoriev, Domantas Jasilionis, Martin McKee, France Meslé, Olga Penina, Judyth Twigg, Jacques Vallin, Denny Vågerö
Journal: The Lancet Regional Health - Europe (2022)

scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
A Comprehensive Immune Cell Atlas of Cystic Kidney Disease Reveals the Involvement of Adaptive Immune Cells in Injury-Mediated Cyst Progression in Mice
Authors: Cheng J. Song, Zhang Li, Ummey Khalecha Bintha Ahmed, Sarah J. Bland, Alex Yashchenko, Shanrun Liu, Ernald J. Aloria, Jeremie M. Lever, Nancy M. Gonzalez, Marisa A. Bickel, Cory B. Giles, Constantin Georgescu, Jonathan D. Wren, Mark L. Lang, Etty N. Benveniste, Laurie E. Harrington, Leo Tsiokas, James F. George, Kenneth L. Jones, David K. Crossman, Anupam Agarwal, Michal Mrug, Bradley K. Yoder, Katharina Hopp, Kurt A. Zimmerman
Journal: Journal of the American Society of Nephrology (2022)

Significance Statement It is widely accepted that injuries to cilia mutant mice accelerate the rate of cystic kidney disease. However, cellular factors that accelerate cystic disease are unknown. By performing single-cell RNA sequencing of all CD45 + immune cells, we found that the subtypes and gene expression profiles of adaptive immune cells are significantly altered among non-injured, aged cystic mice; injury-accelerated cystic mice; and noncystic controls. Surprisingly, deletion of all adaptive immune cells reduced cystic disease in the injury-accelerated model but had no effect on cystic disease in the non-injured model. This differential rescue may be due to unique adaptive immune cell subtypes and ligands that are only present in the injury-accelerated model of cystic disease. Background Inducible disruption of cilia-related genes in adult mice results in slowly progressive cystic disease, which can be greatly accelerated by renal injury. Methods To identify in an unbiased manner modifier cells that may be influencing the differential rate of cyst growth in injured versus non-injured cilia mutant kidneys at a time of similar cyst severity, we generated a single-cell atlas of cystic kidney disease. We conducted RNA-seq on 79,355 cells from control mice and adult-induced conditional Ift88 mice (hereafter referred to as cilia mutant mice) that were harvested approximately 7 months post-induction or 8 weeks post 30-minute unilateral ischemia reperfusion injury. Results Analyses of single-cell RNA-seq data of CD45 + immune cells revealed that adaptive immune cells differed more in cluster composition, cell proportion, and gene expression than cells of myeloid origin when comparing cystic models with one another and with non-cystic controls. Surprisingly, genetic deletion of adaptive immune cells significantly reduced injury-accelerated cystic disease but had no effect on cyst growth in non-injured cilia mutant mice, independent of the rate of cyst growth or underlying genetic mutation. Using NicheNet, we identified a list of candidate cell types and ligands that were enriched in injured cilia mutant mice compared with aged cilia mutant mice and non-cystic controls that may be responsible for the observed dependence on adaptive immune cells during injury-accelerated cystic disease. Conclusions Collectively, these data highlight the diversity of immune cell involvement in cystic kidney disease.
CORRELATION BETWEEN HOSPITAL PROCEDURAL VOLUMES AND OUTCOMES FOR TAVR AND MTEER IN THE UNITED STATES: A STS/ACC TVT REGISTRY ANALYSIS
Authors: Dharam J. Kumbhani, Pratik Manandhar, Anthony A. Bavry, Adnan Chhatriwalla, Jay S. Giri, Michael J. Mack, John D. Carroll, Ambarish Pandey, Andrzej Kosinski, Eric D. Peterson, Tsuyoshi Kaneko, James A. de Lemos, Sreekanth Vemulapalli
Journal: Journal of the American College of Cardiology (2022)
SEX DIFFERENCES IN PROGNOSTIC SIGNIFICANCE OF PLAQUE BURDEN AND DISTRIBUTION MEASURED BY CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY (CCTA) IN YOUNGER PATIENTS
Authors: Anum Asif, Daniel S. Berman, Heidi Gransar, John D. Friedman, Sean W. Hayes, Louise E.J. Thomas, C. Noel Bairey Merz, Balaji Tamarappoo
Journal: Journal of the American College of Cardiology (2022)
2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases
Authors: James M Gwinnutt, Maud Wieczorek, Andra Balanescu, Heike A Bischoff-Ferrari, Annelies Boonen, Giulio Cavalli, Savia de Souza, Annette de Thurah, Thomas E Dorner, Rikke Helene Moe, Polina Putrik, Javier Rodríguez-Carrio, Lucía Silva-Fernández, Tanja Stamm, Karen Walker-Bone, Joep Welling, Mirjana I Zlatković-Švenda, Francis Guillemin, Suzanne M M Verstappen
Journal: Annals of the Rheumatic Diseases (2022)

Objectives A European League Against Rheumatism taskforce was convened to review the literature and develop recommendations on lifestyle behaviours for rheumatic and musculoskeletal diseases (RMDs). Methods Six lifestyle exposures (exercise, diet, weight, alcohol, smoking, work participation) and seven RMDs (osteoarthritis, rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, systemic sclerosis, gout) were considered. The taskforce included health professionals in rheumatology, geriatricians, epidemiologists, public health experts, people with RMDs and exposure domain experts. Systematic reviews were conducted to gather available evidence, from which recommendations were developed. Results Five overarching principles and 18 specific recommendations were defined based on available evidence. The overarching principles define the importance of a healthy lifestyle, how lifestyle modifications should be implemented, and their role in relation to medical treatments. Exercise recommendations highlight the safety and benefits of exercise on pain and disability, particularly among people with osteoarthritis and axial spondyloarthritis. The diet recommendations emphasise the importance of a healthy, balanced diet for people with RMDs. People with RMDs and health professionals should work together to achieve and maintain a healthy weight. Small amounts of alcohol are unlikely to negatively affect the outcomes of people with RMDs, although people with rheumatoid arthritis and gout may be at risk of flares after moderate alcohol consumption. Smokers should be supported to quit. Work participation may have benefits on RMD outcomes and should be discussed in consultations. Conclusions These recommendations cover a range of lifestyle behaviours and can guide shared decision making between people with RMDs and health professionals when developing and monitoring treatment plans.
Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression
Authors: Hao Liu, Danxiu Li, Lina Sun, Hongqiang Qin, Ahui Fan, Lingnan Meng, Ramona Graves-Deal, Sarah E. Glass, Jeffrey L. Franklin, Qi Liu, Jing Wang, Timothy J. Yeatman, Hao Guo, Hong Zong, Shuilin Jin, Zhiyu Chen, Ting Deng, Ying Fang, Cunxi Li, John Karijolich, James G. Patton, Xin Wang, Yongzhan Nie, Daiming Fan, Robert J. Coffey, Xiaodi Zhao, Yuanyuan Lu
Journal: Molecular Cancer (2022)

Epithelial-to-mesenchymal transition (EMT) is a process linked to metastasis and drug resistance with non-coding RNAs (ncRNAs) playing pivotal roles. We previously showed that miR-100 and miR-125b, embedded within the third intron of the ncRNA host gene MIR100HG, confer resistance to cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in colorectal cancer (CRC). However, whether the MIR100HG transcript itself has a role in cetuximab resistance or EMT is unknown.The correlation between MIR100HG and EMT was analyzed by curating public CRC data repositories. The biological roles of MIR100HG in EMT, metastasis and cetuximab resistance in CRC were determined both in vitro and in vivo. The expression patterns of MIR100HG, hnRNPA2B1 and TCF7L2 in CRC specimens from patients who progressed on cetuximab and patients with metastatic disease were analyzed by RNAscope and immunohistochemical staining.The expression of MIR100HG was strongly correlated with EMT markers and acted as a positive regulator of EMT. MIR100HG sustained cetuximab resistance and facilitated invasion and metastasis in CRC cells both in vitro and in vivo. hnRNPA2B1 was identified as a binding partner of MIR100HG. Mechanistically, MIR100HG maintained mRNA stability of TCF7L2, a major transcriptional coactivator of the Wnt/β-catenin signaling, by interacting with hnRNPA2B1. hnRNPA2B1 recognized the N6-methyladenosine (m6A) site of TCF7L2 mRNA in the presence of MIR100HG. TCF7L2, in turn, activated MIR100HG transcription, forming a feed forward regulatory loop. The MIR100HG/hnRNPA2B1/TCF7L2 axis was augmented in specimens from CRC patients who either developed local or distant metastasis or had disease progression that was associated with cetuximab resistance.MIR100HG and hnRNPA2B1 interact to control the transcriptional activity of Wnt signaling in CRC via regulation of TCF7L2 mRNA stability. Our findings identified MIR100HG as a potent EMT inducer in CRC that may contribute to cetuximab resistance and metastasis by activation of a MIR100HG/hnRNPA2B1/TCF7L2 feedback loop.
The Advisory Committee on Immunization Practices’ Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022
Authors: Megan Wallace, Danielle Moulia, Amy E. Blain, Erin K. Ricketts, Faisal S. Minhaj, Ruth Link-Gelles, Kathryn G. Curran, Stephen C. Hadler, Amimah Asif, Monica Godfrey, Elisha Hall, Anthony Fiore, Sarah Meyer, John R. Su, Eric Weintraub, Matthew E. Oster, Tom T. Shimabukuro, Doug Campos-Outcalt, Rebecca L. Morgan, Beth P. Bell, Oliver Brooks, H. Keipp Talbot, Grace M. Lee, Matthew F. Daley, Sara E. Oliver
Journal: MMWR Morbidity and Mortality Weekly Report (2011)

The mRNA-1273 (Moderna) COVID-19 vaccine is a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19.During December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA), and the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use among persons aged ≥18 years (1), which was adopted by CDC.During December 19, 2020-January 30, 2022, approximately 204 million doses of Moderna COVID-19 vaccine were administered in the United States (2) as a primary series of 2 intramuscular doses (100 μg [0.5 mL] each) 4 weeks apart.On January 31, 2022, FDA approved a Biologics License Application (BLA) for use of the Moderna COVID-19 vaccine (Spikevax, ModernaTX, Inc.) in persons aged ≥18 years (3).On February 4, 2022, the ACIP COVID-19 Vaccines Work Group conclusions regarding recommendations for the use of the Moderna COVID-19 vaccine were presented to ACIP at a public meeting.The Work Group's deliberations were based on the Evidence to Recommendation (EtR) Framework,* which incorporates the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach † to rank evidence quality.In addition to initial clinical trial data, ACIP considered new information gathered in the 12 months since issuance of the interim recommendations, including additional follow-up time in the clinical trial, real-world vaccine effectiveness studies, and postauthorization vaccine safety monitoring.ACIP also considered comparisons of mRNA vaccine effectiveness and safety in real-world settings when first doses were administered 8 weeks apart instead of the original intervals used in clinical trials (3 weeks for BNT162b2 [Pfizer-BioNTech] COVID-19 vaccine and 4 weeks for Moderna COVID-19 vaccine).Based on this evidence, CDC has provided guidance * https://www.cdc.
Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT
Authors: William G. Breen, Matthew A. Hathcock, Jason R. Young, Roman O. Kowalchuk, Radhika Bansal, Arushi Khurana, N. Nora Bennani, Jonas Paludo, Jose C. Villasboas Bisneto, Yucai Wang, Stephen M. Ansell, Jennifer L. Peterson, Patrick B. Johnston, Scott C. Lester, Yi Lin
Journal: Journal of Hematology & Oncology (2022)

Abstract Background F-18 fluorodeoxyglucose positron emission tomography computed tomography (PET/CT) is used to assess response of non-Hodgkin lymphoma (NHL) to chimeric antigen receptor T cell (CAR-T) therapy. We sought to describe metabolic and volumetric PET prognostic factors at one month post-CAR-T and identify which patients with partial response (PR) or stable disease (SD) are most likely to subsequently achieve complete response (CR), and which will develop progressive disease (PD) and death. Methods Sixty-nine patients with NHL received axicabtagene ciloleucel CAR-T therapy. One-month post-CAR-T infusion and PET/CT scans were segmented with a fixed absolute SUV maximum (SUVMax) threshold of 2.5 using a semiautomated workflow with manual modification to exclude physiologic uptake as needed. Metabolic tumor volume (MTV), total lesion glycolysis (TLG), SUVMax, and other lesion characteristics were calculated and associated with risk of PD and death. Results Patients with total MTV &gt; 180 cc, presence of bone or parenchymal disease, SUVMax &gt; 10, single lesion TLG &gt; 245 g, or &gt; 2 total lesions had increased risk of death. Patients with total MTV &gt; 55 cc, total TLG &gt; 250 cc, SUV Max &gt; 10, or &gt; 2 total lesions had increased risk of PD. For the subset of 28 patients with PR/SD, higher SUVMax was associated with increased risk of subsequent PD and death. While 86% of patients who had SUVMax ≥ 10 eventually had PD (HR 3.63, 1.13–11.66, p = 0.03), only 36% of those with SUVMax &lt; 10 had PD. Conclusions Higher SUVMax at one month post-CAR-T is associated with higher risk of PD and death. SUVMax ≥ 10 may be useful in guiding early salvage treatment decisions in patients with SD/PR at one month.
EVALUATION OF MICROVASCULAR FUNCTION AND SYSTEMIC INFLAMMATION IN THE ACUTE PHASE OF COVID-19 AND 1 YEAR AFTER RECOVERY: INSIGHTS INTO THE PATHOPHYSIOLOGY OF POST-COVID-19 SYNDROME
Authors: Andrea De Lorenzo, Leticia Sabioni, Vanessa Estato, Hugo Castro-Faria-Neto, Eduardo Tibiriçá
Journal: Journal of the American College of Cardiology (2022)